Exane Derivatives’s CyrusOne Inc Common Stock CONE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-1,689
| Closed | -$152K | – | 1100 |
|
|
2021
Q4 | $152K | Sell |
1,689
-71
| -4% | -$6.03K | 0.04% | 393 |
|
|
2021
Q3 | $136K | Buy |
1,760
+231
| +15% | +$17.4K | 0.03% | 484 |
|
|
2021
Q2 | $112K | Sell |
1,529
-81
| -5% | -$5.9K | 0.03% | 527 |
|
|
2021
Q1 | $109K | Sell |
1,610
-5,215
| -76% | -$362K | 0.03% | 410 |
|
|
2020
Q4 | $499K | Sell |
6,825
-2,424
| -26% | -$176K | 0.15% | 155 |
|
|
2020
Q3 | $648K | Buy |
9,249
+601
| +7% | +$47.1K | 0.19% | 111 |
|
|
2020
Q2 | $629K | Buy |
8,648
+4,494
| +108% | +$320K | 0.17% | 110 |
|
|
2020
Q1 | $256K | Sell |
4,154
-2,886
| -41% | -$176K | 0.07% | 171 |
|
|
2019
Q4 | $445K | Buy |
7,040
+4,055
| +136% | +$278K | 0.08% | 179 |
|
|
2019
Q3 | $236K | Buy |
2,985
+2,971
| +21,221% | +$198K | 0.04% | 223 |
|
|
2019
Q2 | $808 | Hold |
14
| – | – | ﹤0.01% | 566 |
|
|
2019
Q1 | $734 | Hold |
14
| – | – | ﹤0.01% | 522 |
|
|
2018
Q4 | $740 | Hold |
14
| – | – | ﹤0.01% | 583 |
|
|
2018
Q3 | $875 | Buy |
14
+13
| +1,300% | +$841 | ﹤0.01% | 550 |
|
|
2018
Q2 | $59 | Hold |
1
| – | – | ﹤0.01% | 634 |
|
|
2018
Q1 | $51 | Hold |
1
| – | – | ﹤0.01% | 573 |
|
|
2017
Q4 | $60 | Sell |
1
-10,503
| -100% | -$637K | ﹤0.01% | 561 |
|
|
2017
Q3 | $619K | Buy |
+10,504
| New | +$626K | 0.12% | 126 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | -$51 | – | 687 |
|
|
2017
Q1 | $51 | Hold |
1
| – | – | ﹤0.01% | 514 |
|
|
2016
Q4 | $45 | Hold |
1
| – | – | ﹤0.01% | 579 |
|
|
2016
Q3 | $48 | Sell |
1
-7,760
| -100% | -$401K | ﹤0.01% | 564 |
|
|
2016
Q2 | $432K | Buy |
7,761
+6,665
| +608% | +$321K | 0.07% | 143 |
|
|
2016
Q1 | $50K | Buy |
+1,096
| New | +$41.9K | 0.01% | 310 |
|
Other funds holding CONE
Exane Derivatives's CONE Position: Q1 2022 in Review
Exane Derivatives sold out of CyrusOne Inc Common Stock (CONE) in Q1 2022, closing a stake of 1,689 shares — an estimated $152K sold.
Exane Derivatives first reported a position in CONE in Q1 2016 and held it in 23 quarters. The position peaked at $648K in Q3 2020. 3 funds tracked by Wall St. Rank hold CONE as of Q1 2022.
- Exane Derivatives reported no remaining CyrusOne Inc Common Stock position as of Q1 2022 after selling out during the quarter.
- Exane Derivatives sold 1,689 CyrusOne Inc Common Stock shares in Q1 2022, an estimated $152K.
- Exane Derivatives first reported a position in CyrusOne Inc Common Stock in Q1 2016 and held it in 23 quarters.
- Exane Derivatives's CyrusOne Inc Common Stock position peaked at $648K in Q3 2020.
- 3 funds tracked by Wall St. Rank held CyrusOne Inc Common Stock as of Q1 2022.
Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.